Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bridget Moore

Podiatrist Columbia, SC Doctor of Podiatric Medicine

NPI 1669727251 CMS profile 1326273

1730 Saint Julian Pl, Columbia, SC 29204

Open in the dashboard

General payments

$1,534

54 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bridget Moore of Columbia, SC is reported in the CMS Open Payments database as having received $1,534 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $391 11
2024 General $36 1
2023 General $562 12
2022 General $104 6
2021 General $173 8
2020 General $112 5
2019 General $155 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bridget Moore
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Bridget Moore were reported at $391. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Bridget Moore Podiatrist median Middle half National median
2019 $155 $196 $72–$601 $163
2020 $112 $118 $38–$335 $114
2021 $173 $169 $57–$573 $132
2022 $104 $220 $74–$782 $149
2023 $562 $208 $71–$635 $160
2024 $36 $237 $87–$681 $164
2025 $391 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Treace Medical Concepts, Inc. $561 12 payments
  2. Smith+Nephew, Inc. $132 6 payments
  3. ConvaTec Inc. $131 1 payment
  4. Peerless Surgical Inc. $121 3 payments
  5. Paratek Pharmaceuticals, Inc. $88 4 payments
  6. Sebela Pharmaceuticals Inc. $79 5 payments
  7. Integra LifeSciences Corporation $65 4 payments
  8. Musculoskeletal Transplant Foundation Inc. $65 2 payments
  9. Horizon Therapeutics plc $44 1 payment
  10. Abbott Laboratories $30 2 payments
  11. Other $218 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,275 51 payments
  2. Travel and Lodging $260 3 payments
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM $284 5 payments
  2. INNOVAMATRIX AC $148 2 payments
  3. TMC NANOPLASTY SYSTEM $120 1 payment
  4. NUZYRA $88 4 payments
  5. NAFTIN $79 5 payments
  6. LAPIPLASTY SYSTEM 1 $78 3 payments
  7. GRAFIX PL $50 2 payments
  8. Bone Anchors with Arthroscopic Delivery System $44 1 payment
  9. KRYSTEXXA $44 1 payment
  10. SALTO TALARIS TOTAL ANKLE PROSTHESIS $43 3 payments
  11. Other $734 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

726

Median for Podiatry: 160

Drug cost

$31,810

Median for Podiatry: $2,368

Branded share of claims

39.9%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jublia Efinaconazole Brand 11 $17,109
Naftifine Hcl Generic 13 $3,713
Clotrimazole Generic 82 $2,384
Ciclopirox Ciclopirox Olamine Brand 64 $1,989
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 111 $1,783
Ketoconazole Generic 25 $599
Ciclopirox Generic 20 $430
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 27 $429
Gabapentin Generic 32 $351
Ammonium Lactate Generic 19 $338

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$135,287

Medicare's payments for the services billed

Medicare patients

462

Average age 74

Services billed

2,744

305 women, 157 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 59%
Arthritis 55%
Chronic kidney disease 34%
Ischemic heart disease 27%
Heart failure 20%
Atrial fibrillation 15%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record